IPM Take
The real issue is not whether ctDNA can detect recurrence risk after colon cancer surgery. The sharper question is whether health systems know what to do with that risk. A positive MRD result may identify a patient at higher risk, but if it does not trigger a validated escalation, de-escalation or surveillance strategy, reimbursement and patient counselling become difficult. This is exactly where precision diagnostics move from science into policy.
Executive Summary
A 2026 Journal of Clinical Oncology article, “Circulating Tumor DNA for Minimal Residual Disease in Colon Cancer: Ready for Prime Time?”, addresses the growing use of ctDNA to detect molecular residual disease after colon cancer treatment. The article reflects a wider shift: ctDNA is increasingly recognised as a prognostic tool, but routine clinical action based on MRD results still depends on stronger evidence, trial data and clear guidance. NCCN-related reporting has also noted a cautious position: ctDNA is prognostic in colon and rectal cancer, but routine use outside clinical trials and treatment de-escalation based on ctDNA findings are not recommended because evidence remains insufficient.
Why it matters
- Clinicians: Need clear guidance on how MRD results should affect adjuvant treatment, surveillance intensity and patient counselling.
- Payers / HTA bodies: Must decide whether to fund testing before there is full agreement on which clinical actions should follow positive or negative results.
- Patients / advocates: Should watch whether MRD testing leads to better outcomes, not only earlier risk information that may increase anxiety without a validated pathway.
Previously, post-surgery colon cancer decisions relied mainly on tumour stage, pathology, imaging and clinical risk factors. ctDNA adds a more molecular layer by looking for residual tumour DNA in blood after treatment.
What is changing now is the pressure to move MRD testing into routine pathways. The policy problem is timing. Testing may identify patients at higher recurrence risk earlier than imaging, but systems still need rules for treatment escalation, treatment de-escalation, surveillance, reimbursement and informed consent.
The affected population is mainly people treated for colon cancer where recurrence risk and adjuvant-treatment decisions are clinically important. The access question is not simply whether the test is technically useful. It is whether a positive or negative result leads to a decision that improves outcomes.
For IPM, colon cancer MRD testing is a near-perfect access question: a promising diagnostic is arriving before the implementation pathway is fully settled. The platform should frame it as an evidence-threshold issue, not as a fully routine-ready test.
